Country: Singapore
Language: English
Source: HSA (Health Sciences Authority)
CLORAZEPATE DIPOTASSIUM
SANOFI-AVENTIS SINGAPORE PTE. LTD.
N05BA05
5 mg
CAPSULE
ORAL
Prescription Only
SANOFI WINTHROP INDUSTRIE
1988-05-21
QUALITATIVE AND QUANTITATIVE COMPOSITION Dipotassium clorazepate................................. 5mg Excipients: potassium carbonate, talc. PHARMACEUTICAL FORM Capsule CLINICAL PARTICULARS THERAPEUTIC INDICATIONS • Reactional anxiety, in particular adaptation disorders with anxious mood and post-traumatic anxiety. • Adjunctive therapy for anxiety in neuroses (in particular hysteria, hypochondria, phobia). • Anxiety associated with severe or painful somatic disorders. • Generalized anxiety. • Anxiety attack. • Prevention and treatment of delirium tremens. • Alcohol withdrawal. Panic disorder does not constitute an indication. POSOLOGY AND METHOD OF ADMINISTRATION DURATION Treatment should be as short as possible and the patient should be reassessed regularly and the need for continued treatment should be evaluated, especially in case the patient is symptom free. In most patients, the overall duration of treatment should not exceed 4 to 12 weeks, including the period of dose tapering (see section “Special warnings and special precautions for use”). • Reactional anxiety, adjunctive therapy for anxiety in neuroses, anxiety associated with severe or painful somatic disorders: 4 to 12 weeks, including dose tapering. • Generalized anxiety: long term treatment upon specialist’s advice. • Anxiety attacks: short term treatment • Prevention and treatment of _delirium tremens_: a few days. • Alcohol withdrawal: treatment lasting 3 to 6 weeks surrounding the withdrawal period. Treatment should always be tapered off gradually. DOSE In all cases, treatment must be started with the lowest recommended dose. The maximum daily dose of 90 mg per day Read the complete document